- Home
- CTSO vs SACH Comparison
CTSO vs SACH Comparison
Compare CTSO & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- SACH
- Stock Information
- Founded
- CTSO 1997
- SACH 2010
- Country
- CTSO United States
- SACH United States
- Employees
- CTSO N/A
- SACH N/A
- Industry
- CTSO Medical/Dental Instruments
- SACH Real Estate Investment Trusts
- Sector
- CTSO Health Care
- SACH Real Estate
- Exchange
- CTSO Nasdaq
- SACH Nasdaq
- Market Cap
- CTSO 51.6M
- SACH 50.7M
- IPO Year
- CTSO N/A
- SACH 2017
- Fundamental
- Price
- CTSO $1.15
- SACH $1.09
- Analyst Decision
- CTSO Strong Buy
- SACH Buy
- Analyst Count
- CTSO 3
- SACH 2
- Target Price
- CTSO $4.67
- SACH $2.25
- AVG Volume (30 Days)
- CTSO 147.4K
- SACH 387.1K
- Earning Date
- CTSO 03-06-2025
- SACH 03-31-2025
- Dividend Yield
- CTSO N/A
- SACH 22.22%
- EPS Growth
- CTSO N/A
- SACH N/A
- EPS
- CTSO N/A
- SACH N/A
- Revenue
- CTSO $37,739,531.00
- SACH $10,951,064.00
- Revenue This Year
- CTSO $9.20
- SACH N/A
- Revenue Next Year
- CTSO $11.64
- SACH N/A
- P/E Ratio
- CTSO N/A
- SACH N/A
- Revenue Growth
- CTSO 1.80
- SACH N/A
- 52 Week Low
- CTSO $0.70
- SACH $1.00
- 52 Week High
- CTSO $1.61
- SACH $4.64
- Technical
- Relative Strength Index (RSI)
- CTSO 55.74
- SACH 44.17
- Support Level
- CTSO $1.06
- SACH $1.05
- Resistance Level
- CTSO $1.61
- SACH $1.15
- Average True Range (ATR)
- CTSO 0.13
- SACH 0.06
- MACD
- CTSO 0.01
- SACH 0.01
- Stochastic Oscillator
- CTSO 29.34
- SACH 45.00
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a United States-based real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.